ClinicalTrials.gg
Not yet recruitingNCT07485595Updated Apr 8, 2026

A Study of the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression

A Phase 2/3 interventional study of Placebo group and JS1-1-01 low-dose group in Depression, sponsored by Tasly Pharmaceutical Group Co., Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Tasly Pharmaceutical Group Co., Ltd (part of China Resources Pharmaceutical Group Limited) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 358 studies in Depression with a site in China — 119 open to participants now, 138 under way, 3 of them phase 3. Depression · China.

Planned enrollment
106th of 284
180 · median 129
Started
2026
with 37 others
Phase 2/3
6 of 358
1 open now
Primary completion
2026-12
later than 79 of 137 live
Registered
328th of 358
by date

Among the 358 studies in Depression with a site in China, this one is the 106th largest by planned enrollment of the 284 interventional ones that give a count, is one of 38 that started in 2026, is one of 6 in phase 2/3, reaches primary completion later than 79 of the 137 other live ones, and was the 328th registered.

Depression

8,602 studies on the registry are indexed under Depression; 1,735 are open to participants now.

Browse Depression studies →

Open to participants now

119 of the 358 studies in Depression with a site in China are open now. Recruiting first, the newest first:

114 more — sign in →

All 119 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,099 Depression studies recruiting now, 474 (43%) set no upper age limit and 524 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 358 studies in Depression with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression

03

Conditions studied

  • Depression

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age range from 18 to 65 years old (including boundary values), both male and female;
  2. Single or recurrent episodes that meet the diagnostic criteria for depression in (Diagnostic and Statistical Manual of Mental Disorders, 5th edition);For patients with a single episode, the duration of this depressive episode must be ≥90 days.
  3. Screening and baseline periods, the total score of the Montgomery Asperger Depression Rating Scale (MADRS) was ≥ 26 points;
  4. Screening and baseline periods, with a Clinical Global Impression Scale Disease Severity (CGI-S) score of ≥ 4 points;
  5. Voluntary participation in clinical trials, able to sign forms, and able to understand and comply with research procedures.

Exclusion criteria

Exclusion Criteria:

  1. Individuals with a history of severe drug allergies or allergies to Piper Piper (pepper plant) ;
  2. Those who have used at least two antidepressants in sufficient dosage and duration (treated according to the maximum dosage in the instructions for at least 4 weeks) in a single or current episode in the past but still have no effect;
  3. The patients of depression secondary to other mental or physical illnesses;
  4. Patients of depression with accompanying psychiatric symptoms;
  5. Significant suicidal attempt or behavior within the past year, with a score of ≥ 3 on the 10th item (suicidal ideation) of the MADRS scale;
  6. Individuals with a history of epileptic seizures (excluding convulsions caused by febrile seizures in children);
  7. Individuals who have received depression related systemic physical therapy within 3 months prior to their first administration: modified electroconvulsive therapy (MECT), transcranial magnetic stimulation (TMS), vagus nerve stimulation (VNS), deep brain stimulation (DBS), phototherapy, or systemic psychotherapy;
  8. Systematically receiving antidepressant treatment within the first 2 weeks of randomization, or discontinuing antidepressant medication for less than 5 half-lives before randomization;
  9. Those with severe unstable cardiovascular and cerebrovascular diseases, respiratory system diseases, gastrointestinal diseases, liver diseases, kidney diseases, blood diseases, endocrine diseases, or a history of such physical diseases;
  10. Accompanied by a history of malignant tumors (excluding cured skin basal cell carcinoma and cervical carcinoma in situ);
  11. Screening or baseline abnormalities that have clinical significance and are deemed unsuitable for inclusion by investigators, such as male ≥ 450 ms, female QTcF ≥ 470 ms, or having a history of long QT syndrome;
  12. During the baseline period, those with a reduction rate of ≥ 25% in the MADRS scale score compared to the screening period;
  13. A history of symptomatic orthostatic hypotension (i.e. orthostatic syncope) with clinical significance;
  14. During the screening or baseline period, is above 2 times the value, and or AST is above 2 times the upper limit of normal value; Cr is higher than 1.2 times the upper limit of normal value;
  15. Thyroid dysfunction (TSH above 1.2 times the upper limit of normal value or below 0.8 times the lower limit of normal value) or the presence of hyperthyroidism or hypothyroidism determined by the investigators; Individuals with a history of elevated intraocular pressure or narrow angle glaucoma;
  16. Screening period, drug abuse screening positive individuals;
  17. A history of alcohol dependence within one year prior to screening(Drinking alcohol for more than 5 years, equivalent ethanol intake, daily alcohol consumption: men >40 g/d, women >20 g/d; drinking ≤5 years, equivalent ethanol intake, history of heavy drinking (>80 g/d) within 2 weeks);
  18. Pregnant and lactating women, male or female subjects who have a family planning or are unable to take effective measures within 30 days after signing the form and ending the trial;
  19. Screening for individuals who have participated in clinical trials and taken drugs within the first 30 days;
  20. The investigators believe that the subjects have poor compliance or there are other clinical, social, or family factors that are not suitable for enrollment.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Placebo comparator
    Placebo group

    Drug: Placebo group

  • Experimental
    JS1-1-01 low-dose group

    Drug: JS1-1-01 low-dose group

  • Experimental
    JS1-1-01 high-dose group

    Drug: JS1-1-01 high-dose group

Interventions

  • DrugPlacebo group

    (2 of 50 mg JS1-1-01 placebo tablets+1 of 75 mg JS1-1-01 placebo tablets)/time, 2 times per day, administered postprandial, for 8 consecutive weeks.

    Also known as: JS1-1-01 placebo tablet

  • DrugJS1-1-01 low-dose group

    (2 of 50 mg JS1-1-01 placebo tablets+1 of 75 mg JS1-1-01 tablets)/time, 2 times per day, administered postprandial, for 8 consecutive weeks.

    Also known as: JS1-1-01 tablet ; JS1-1-01 placebo tablet

  • DrugJS1-1-01 high-dose group

    (2 of 50 mg JS1-1-01 tablets+1 of 75 mg JS1-1-01 placebo tablets)/time, 2 times per day, administered postprandial, for 8 consecutive weeks.

    Also known as: JS1-1-01 tablet ; JS1-1-01 placebo tablet

06

What researchers measure

Primary outcomes

  1. The change in MADRS total score from baseline

    There are a total of 10 projects in Montgomery-Asberg Depression Rating Scale(MADRS), each with a 7-point scoring system ranging from 0 to 6 points. The higher the score, the more severe the degree of depression.

    Time frame: 8 weeks

Secondary outcomes

  1. The change in HAMD-17 total score from baseline

    There are a total of 17 projects in Hamilton Depression Scale-17(HAMD-17). Scores are distributed on a scale of 0 to 53. A score above 24 indicates severe depression, a score of 17 indicates moderate depression, and a score below 7 indicates no depressive symptoms.

    Time frame: 8 weeks

  2. The effective rate of MADRS

    The effective definition of MADRS is that the reduction rate of MADRS score relative to baseline is ≥ 50%

    Time frame: 8 weeks

  3. The effective rate of HAMD-17

    The effective definition of HAMD-17 is that the reduction rate of HAMD-17 score relative to baseline is ≥ 50%.

    Time frame: 8 weeks

  4. The response rate of MADRS

    The response definition of MADRS is that the score ≤ 12 points.

    Time frame: 8 weeks

  5. The response rate of HAMD-17

    he response definition of HAMD-17 is that the score ≤ 7 points.

    Time frame: 8 weeks

  6. The change in MADRS Single item score from baseline

    Each single item has a 7-point scoring system ranging from 0 to 6 points. The higher the score, the more severe the degree of depression.

    Time frame: 8 weeks

  7. The change in HAMD-17 factor score from baseline

    1. Items scored 0-4 (5-point scale, 8 items) Depressed mood, feelings of guilt, suicide, work and interests, retardation, agitation, psychic anxiety, somatic anxiety 2. Items scored 0-2 (3-point scale, 9 items) Difficulty falling asleep, insomnia during sleep, early awakening, gastrointestinal symptoms, general somatic symptoms, genital symptoms, hypochondriasis, weight loss, insight. The higher the score, the more severe the degree of depression.

    Time frame: 8 weeks

  8. The change in CGI-S total score from baseline

    Perform the Clinical Global Impression Scale (CGI-S) score from Visit 1 to Visit 7,The highest score is 7 points, and the higher the score, the more severe the condition will be.

    Time frame: 8 weeks

  9. Proportion of participants with a CGI-S score of 1/2

    Perform the Clinical Global Impression Scale (CGI-I) score from Visit 3 to Visit 7.The highest score is 7 points, and the higher the score, the more severe the condition will be.

    Time frame: 8 weeks

  10. Proportion of CGI-I Scores on the Clinical Global Impression Scale

    Perform the Clinical Global Impression Scale (CGI-I) score from Visit 3 to Visit 7.The highest score is 7 points, and the higher the score, the more severe the condition will be.

    Time frame: 8 weeks

  11. The change in HAMA total score from baseline

    There are a total of 14 projects in Hamilton Scale(HAMA).The total score ranges from a minimum of 0 to a maximum of 56. The higher the score, the more severe the anxiety.

    Time frame: 8 weeks

Other outcomes

  1. The change in ISI total score from baseline

    There are a total of 7 projects in Insomnia Severity Index(ISI) . The total score ranges from a minimum of 0 to a maximum of 28. The higher the score, the more severe the degree of insomnia.

    Time frame: 8 weeks

  2. The change in DSST total score from baseline

    Participants are required to match symbols with numbers according to the coding key as many as possible within 90 seconds. One point is awarded for each correct matching item; the first 10 sample items are unscored and not timed. The total score ranges from a minimum of 0 to a maximum of 90. Higher scores indicate better cognitive processing speed and represent a superior outcome. The lower the score, the worse of the cognitive function.

    Time frame: 8 weeks

  3. The change in PDQ-D total score from baseline

    The total score ranges from a minimum of 0 to a maximum of 80. The higher the score, the worse of the cognitive function.

    Time frame: 8 weeks

07

Study locations

1 site
  • Gang Wang
    Beijing, Beijing Municipality, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Dec 2026, 8 months later.

Of 32 phase 2/3 interventional studies under Depression, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 56. This study's planned 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2026
First posted
Mar 20, 2026
StartEst.
Apr 30, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07485595
Responsible party
Sponsor
First posted
Mar 20, 2026
Start date
Apr 30, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 8, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion